A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma

Brittain, Dominic E. A.; D’Andrea, Peter; Gruen, Emilie; Hosoe, Motoi; Jain, Dipika; Jauernig, Juergen; Pethe, Abhijit; Scosyrev, Emil; Tanase, Ana-Maria; Tillmann, Hanns-Christian

doi:10.1007/s12325-021-02025-w

Cited by 6 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IND is called "Ultra-LABA" because of its long duration of action of over 24 h. This drug has recently been approved for asthmatic patients. Indeed, IND is indicated for the treatment of asthma in a once-daily dose dual combination with a corticosteroid, and a triple combination with a corticosteroid and a LAMA [29,30]. In addition, benefits in terms of the bronchodilation effect on COPD patients have been demonstrated in combination with the LAMA TIO [23].…”

Section: Introductionmentioning

confidence: 99%

Optimization of Long-Acting Bronchodilator Dose Ratios Using Isolated Guinea Pig Tracheal Rings for Synergistic Combination Therapy in Asthma and COPD

et al. 2022

View full text Add to dashboard Cite

The co-administration of a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), has been shown to be beneficial in the management of non-communicable chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The resulting relaxation of the airways can be synergistically enhanced, reducing symptoms and optimizing lung function. This provides an insight into more effective treatments. In this study, the LABAs formoterol fumarate dihydrate (FOR) and indacaterol maleate (IND) were each associated with tiotropium bromide monohydrate (TIO) to assess their synergistic potential. This was done using an appropriate ex vivo model of isolated perfused guinea pig tracheal rings, and pharmacological models of drug interaction. Among the dose ratios studied for both types of combination, a higher synergistic potential was highlighted for FOR/TIO 2:1 (w/w). This was done through three steps by using multiple additions of drugs to the organ baths based on a non-constant dose ratio and then on a constant dose ratio, and by a single addition to the organ baths of specific amounts of drugs. In this way, the synergistic improvement of the relaxant effect on the airways was confirmed, providing a basis for improving therapeutic approaches in asthma and COPD. The synergy found at this dose ratio should now be confirmed on a preclinical model of asthma and COPD by assessing lung function.

show abstract

Section: Introductionmentioning

confidence: 99%